NEWS

  • New Research Collaboration with Janssen Biotech

    Immune Biosolutions Enters into a Research Collaboration and License Agreement with Johnson & Johnson Innovation to Identify and Develop Therapeutic Antibodies for Multiple Targets Sherbrooke, QC – August 6, 2018 – Immune Biosolutions Inc. (IBio), a JLABS @ Toronto resident company, today announced a research collaboration and license agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The agreement, facilitated by Johnson & Johnson Innovation LLC, will focus initially on the discovery...
  • Immune Biosolutions Participating in Futurpreneur's Growth Accelerator

    After winning a pitch competition earlier this year, Immune Biosolutions' founders are participating this week in the Futurpreneur's Growth Accelerator in Toronto. Immune Biosolutions was recognized among those with the greatest potential to impact the market in new ways. The founders are grateful to Futurpreneur, Spin Master, Morrison Financial and Dentons Canada for the invitation and look forward to creating useful connections that will foster the continued growth of the company.  
  • CQDM to support a $1.1 million Immune Biosolutions' research project.

    CQDM to support a $1.1 million research and development project for Immune Biosolutions’ next-generation of anti-cancer treatment BOSTON, JUNE 6, 2018 – CQDM is pleased to announce the funding of a new $1.1 million research project in conjunction with financial contributions from lead industrial partner, Immune Biosolutions, and co-funding from:  Cancer Research Society, Mitacs, Centre de Recherche du Centre Hospitalier Universitaire de Sherbrooke and TransferTech. The funds will be used by the Université de Sherbrooke’s Professors Fernand Gobeil, Philippe...
  • Immune Biosolutions to Present at ICCS 2018

    Immune Biosolutions has been selected to present at the 7th International Cancer Cluster Showcase 2018 in Boston during the BIO Convention week (June 4-7, 2018). Chief Executive Officer Frédéric Leduc will present the company’s cutting-edge Nebula Discovery Platform and an update on its most advanced therapeutic candidate in oncology. Details for the presentation are as follows: Date: Monday, June 4, 2018 Time: 2:20 PM EST Location: Boston Convention & Exhibition Center (BCEC) Boston, 415 Summer St, Boston, Ma 02210...
  • Immune Biosolutions delegates to participate to BIO Convention 2018 in Boston

    Immune Biosolutions' team will once again participate to one of the largest life sciences convention in North America. Frédéric Leduc, Simon Gaudreau, and Yolaine Robitaille will be very active at the Quebec's Pavillion (booth 751). They are looking to meet with potential partners and collaborators to put in place new discovery programs.
  • Immune Biosolutions to participate to Knowledge for Growth 2018 in Belgium

    Chief executive officer, Frédéric Leduc, and chief scientific officer, Simon Gaudreau, will be representing Immune Biosolutions next week at the 14th edition of  Knowledge for Growth business conference that will be held in Belgium.
  • Immune Biosolutions to Present at Bio€quity Europe 2018

    Immune Biosolutions, a Canadian biotech company specialized in the discovery and engineering of humanized chicken antibodies, will present its proprietary Nebula Discovery platform as well as pre-clinical data for one of its lead candidate in oncology at the 19th Bio€quite Europe Meeting in Ghent, May 14-16 2018. Details of the presentation are as follows: Date: Tuesday, May 15, 2018 Time: 14:20-14:30 Location: Level 1, Rector Gillis, Ghent Town Hall, Ghent, Belgium
  • Self vs non-self in avians and mammals

    Xenobiotic and pathogen recognition by the immune system relies on ability to discriminate self and non-self epitopes. Throughout their maturation process, antibodies are selected in a both positive and negative manner. This allows to trigger an immune response only against foreign substances such pathogens, not in the host organism. Mammals and avians are separated by nearly 300 000 000 years of evolution. Consequently, minor changes in genome sequences between mammals are reflected by high similarity in protein primary sequences, whereas the difference...
  • Immune Biosolutions selected for JLABS @ Toronto

    Immune Biosolutions selected for JLABS @ Toronto Immune Biosolutions is among the 22 growing businesses selected for JLABS @ Toronto. Initiated and managed by the pharmaceutical company Johnson & Johnson, JLABS are a network of 6 tech incubators focusing on life sciences. The newest facility, JLABS @ Toronto, located in the MaRS district, is the first located outside the US. JLABS resident companies Companies hosted in the state-of-the-art infrastructures of JLABS have access to J&J's scientific, operational and business resources...
  • Immune Biosolutions will continue its growth at EspaceLabz

    Immune Biosolutions, a JLABS @ Toronto resident, is pleased to announce the relocation of its Sherbrooke headquarters and laboratories in the new EspaceLabz center, located in the Sherbrooke’s Scientific Park. In addition to providing additional space, the new facility will grant access to state-of-the-art equipment to follow the increasing demand for Immune Biosolutions' Nebula Antibody Platform, and will allow additional R&D initiatives in the development of new life- saving technologies. This marks an important milestone for Immune Biosolutions. With recent...

Articles 1 à 10 sur un total de 12

Page :
  1. 1
  2. 2